Home > Boards > US Listed > Biotechs >

Regen BioPharma Inc. (RGBP)

RGBP RSS Feed
Add RGBP Price Alert      Hide Sticky   Hide Intro
Moderator: gotinearly, DTGoody, cjstocksup, ronrooster, Skiluc, Knapper
Search This Board: 
Last Post: 5/8/2021 6:42:07 AM - Followers: 861 - Board type: Free - Posts Today: 2

Picture

Regen BioPharma 
Followers: 388 Since 10/10/19

 0.000x  Ticker Symbol: RGBP 
Last iBox update 08/09/2020 4PM by CrazyKar123

Barchart


HOT NEWS 

Cell Therapy Technologies Market – Global Industry Insights and Forecast year 2018-2025
SAN DIEGO , Aug. 15, 2019 /PRNewswire/ -- Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP),
Regen BioPharma Inc. Files Immuno-Oncology Patent Application on Synergy of Cannabidiol With NR2F6 Modulation


All other Regen BioPharma News
https://www.regenbiopharmainc.com/company-news.html




 
 

Regen BioPharma, Inc. 4700 Spring Street, Suite 304
La Mesa, CA 91942 U.S.A.


Telephone: (619) 702-1404
Fax: (619) 330-2328




Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP)  focused on the immunology and immunotherapy space. The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing small molecule therapies for treating cancer and autoimmune disorders by modulating the Checkpoint NR2F6.  The company also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).






 

Product Pipeline | Regen BioPharma, Inc.

Small Molecules Targeting Cancer and Autoimmunity

Regen has identified and filed patents on small molecules that activate and inhibit a novel gene (NR2F6) which controls how the immune system reacts to cancer cells and to inflammatory responses.
  • Objective is to identify small molecules that can activate and inhibit NR2F6
    ?Currently in pre-clinical development 
    Initial indications (inhibitor): bladder cancer, myelodysplastic syndrome, lung cancer
    Initial indications (activator): rheumatoid arthritis, inflammatory bowel disease, psoriasis
    Additional indications include solid tumors, acute leukemia and GVHD
 

HemaXellerate

Aplastic Anemia Stem Cell Therapy – HemaXellerate – IND #15376 CLEARED TO PROCEED TO PHASE I / II CLINICAL TRIALS
HemaXellerate is a personalized cellular therapeutic product designed to stimulate blood production in patients whose bone marrow is not properly functioning.
  • Fat stem cell based product to treat bone marrow that has been damaged
    Bone marrow damage occurs from radiation, chemo, or chronic conditions
    HemaXellerate uses patient’s own fat as source of endothelial cells to heal damaged bone marrow 
    ?United States Food and Drug Administration Investigational New Drug Application cleared (IND #15376)



     

dCellVax 

Breast Cancer – dCellVax - IND #16200
CellVax is a dendritic cell based immunotherapy that stimulates the patient’s immune system through a process called “gene silencing.”
  • 10 advanced breast cancer patients
    Efficacy endpoints at 6 and 12 months
    Establishment of safety will allow for rapid expansion of patient numbers 
    Currently addressing FDA questions with Dr. Santosh Kesari, head of UCSD Neuro-Oncology program 


     

DiffronC

Myelodysplastic Syndrome Gene Silencing – DiffronC
DiffronC is a novel form of therapy called differentiation therapy that is expected to have much milder toxicity than chemotherapy. The mechanism of action is to correct the specific genes that prevent the myelodysplastic syndrome stem cell from producing mature blood cells.
  • siRNA silencing of our newly discovered cancer stem cell target gene
    Silencing using DiffronC induces differentiation of cancer cells 
    Initial indication is treatment of myelodysplastic syndrome 
    Other indications include solid tumors and acute leukemia



     

Telomeres & Genomic Integrity

Stem cells and cancer cells have found ways of maintaining their telomeres in a state that prevents senescence. Our research in to the cancer stem cell has given us a molecular pathway that can be manipulated to expand stem cells and maintain telomeres.
  • Telomeres are protective structures at the ends of chromosomes that enable cell divisions
    Telomere attrition is involved in aging, cancer and genetic mutations 
    We are developing drugs that modulate telomere maintenance 
    In pre-clinical development for indications of solid cancers and acute leukemia




     
Image result for cbd


 

Regen BioPharma, Inc. Examines Combining Cannabidiol (CBD) With Its Lead NR2F6 Agonist To Treat for Inflammatory Bowel Disease

 

SAN DIEGO, January 8, 2019 /PRNewswire/ --   https://www.otcmarkets.com/stock/RGBP/news/Regen-BioPharma-Inc-Examines-Combining-Cannabidiol-CBD-With-Its-Lead-NR2F6-Agonist-To-Treat-for-Inflammatory-Bowel-Disea?id=214869

Regen BioPharma, Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), reports its researchers have determined that combining its lead NR2F6 small molecule agonist with Cannabidiol (CBD) may provide a dynamic therapy for treating inflammatory bowel disease (IBD). Currently, there are a number of pre-clinical and clinical studies being conducted by other companies regarding pain management that suggest potential benefits of CBD. Regen believes that CBD may augment the Company's small molecule therapies for autoimmune disorders, in this case specifically IBD.

IBD is a disease caused by persistent and chronic inflammation of the gastrointestinal tract and is a term that refers to both ulcerative colitis and Crohn's disease. Current treatments include non-specific immune suppressors such as steroids as well as newer drugs recently approved by the FDA. The IBD market size is estimated at $6.7 billion global and projected to be $7.6 billion by 2023.There are currently no non-steroidal therapies  available to IBD sufferers.

"Our ex-vivo studies with RG-NAH005 (Regen's small molecule agonist) support moving the drug into animal studies where we can measure the effect of the drug on different diseases," says Harry Lander, Ph.D., President and Chief Scientific Officer of Regen.  "We believe incorporating CBD in our studies will allow us to potentially strengthen positive outcomes for patients."

The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 small molecule program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity and chronic inflammation.

"We are pleased that RG-NAH005 has shown a safety profile that allows us to move it into animal studies," says David Koos, Ph.D., Chairman & CEO of both Regen BioPharma, Inc. and Zander Therapeutics, Inc. "We are enthusiastic that combining CBD with our small molecule agonist will potentially make our small molecule therapy for IBD more dynamic is its approach to treating this disease."

 

 







REMEMBER
Always research for yourself BEFORE you buy in the OTC !!!!

RGBP
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
News News Alert: Current Report Filing (8-k) 05/07/2021 02:42:53 PM
PostSubject
#58183  Sticky Note HERE COMES THE INSTITUTIONAL INVESTORS!! OTCShotCaller 04/25/21 12:00:41 PM
#51245  Sticky Note 127 Articles for Regen. Enjoy. Skiluc 04/16/21 01:30:56 PM
#44581  Sticky Note RGBP Product Pipeline Golden_Cross 04/09/21 09:32:06 PM
#41420  Sticky Note RGBP/Zander patents... gotinearly 03/29/21 09:43:29 AM
#37964  Sticky Note Look into filing history of RGBP, delinquent, lawsuit, ronrooster 08/17/20 10:58:45 AM
#62441   Could explain why the stop sign and why Fdc4 05/08/21 06:42:07 AM
#62440   There is no clean breakaway gap to fill LoveAndLight 05/08/21 04:34:28 AM
#62439   and we have a new gap, imo to SmokeSignals 05/07/21 11:26:22 PM
#62438   Agree. Let’s see how it goes. Welcome2Pinkyland 05/07/21 11:25:54 PM
#62437   The tide is turning, slowly but surely. The trademax42 05/07/21 11:01:15 PM
#62433   thank you zard!! mr wizard!! youre the stokbrokin 05/07/21 08:59:41 PM
#62430   $RGBP hold for gold $$ Welcome2Pinkyland 05/07/21 08:11:58 PM
#62429   Ahahahhaha HorizenBull 05/07/21 07:58:13 PM
#62428   #DDAmanda Chart (CLASSIC Insider Play) on: $RGBP : Zardiw 05/07/21 07:55:40 PM
#62427   His post was from 2015. Madguppy 05/07/21 07:54:26 PM
#62426   looks like PAUL maybe done here....he shook this ursa 05/07/21 07:39:50 PM
#62425   Nifty joe botts 05/07/21 07:38:04 PM
#62424   Keep buying joe botts 05/07/21 07:37:13 PM
#62423   Leads Straight to the bowels of Stinky-PinkyLand. Homebrew 05/07/21 07:35:38 PM
#62422   Good joe botts 05/07/21 07:35:18 PM
#62421   Ummm.there was news? joe botts 05/07/21 07:34:18 PM
#62420   so let me get this straight KCL Therapeutics marcus5859 05/07/21 07:32:37 PM
#62419   Well golly joe botts 05/07/21 07:31:47 PM
#62418   I want to like this but damn those CashCowMoo 05/07/21 07:27:09 PM
#62417   Yuup Nysegolfa 05/07/21 07:23:25 PM
#62416   does a scam company do this? marcus5859 05/07/21 07:22:09 PM
#62415   Science is prevailing. We beat the MMs today. RGBP Brianwhi 05/07/21 07:20:48 PM
#62414   cutting edge science technology cannot be stifled with marcus5859 05/07/21 07:19:55 PM
#62413   This room was so exciting today a lot marcus5859 05/07/21 07:18:16 PM
#62412   $RGBP is using the same science as Moderna marcus5859 05/07/21 07:17:25 PM
#62411   who,s name is in this report Regen BioPharma marcus5859 05/07/21 07:16:00 PM
#62410   rgbp Item 8.01 Other Events. marcus5859 05/07/21 07:13:36 PM
#62403   * * $RGBP Video Chart 05-07-2021 * * ClayTrader 05/07/21 05:47:04 PM
#62398   Great! maperatpogi 05/07/21 05:24:37 PM
#62396   When they(including ONPH) prove they can treat cancer hunterj20 05/07/21 05:00:01 PM
#62393   lol we’ve acquired shares of legit company.... that’s bluebird50 05/07/21 04:56:09 PM
#62391   yo, wack some buys RGBP, YOUR HERE! smh..comi SmokeSignals 05/07/21 04:54:43 PM
#62389   How is it that I am the only SidVicious 05/07/21 04:54:12 PM
#62386   what plan? Licensing IP with no idea of SidVicious 05/07/21 04:50:47 PM
#62384   Can't wait to see what happens on Monday. SidVicious 05/07/21 04:46:37 PM
#62383   It’s obvious he has implemented the plan.... refer bluebird50 05/07/21 04:46:07 PM
#62382   Koos used to put out letters to his SidVicious 05/07/21 04:43:36 PM
#62381   Koos won't even buy any of his own SidVicious 05/07/21 04:41:08 PM
#62380   Koos abandoned patents. Sounds about right as he SidVicious 05/07/21 04:40:15 PM
#62379   And Popeye too! Thanks and a great The Law (f/k/a emz) 05/07/21 04:38:50 PM
#62378   Past hour.. almost 10,000 reads.. "if your not moondogaz 05/07/21 04:38:40 PM
#62377   So Konman Koos can't even afford to put SidVicious 05/07/21 04:37:49 PM
#62376   For those several that asked: Yes, of Course! Skiluc 05/07/21 04:33:35 PM
#62375   you are the BATMAN !! thank u dmchas 05/07/21 04:30:24 PM
#62373   Yupppp thats why I'm here!!! $RGBP WizardOfWallstreet 05/07/21 04:27:48 PM
#62372   Thanks for the info!! Madguppy 05/07/21 04:27:47 PM
#62371   Added to round up to 5 mil today 1floorguy 05/07/21 04:22:45 PM
#62370   Same to you Skiluc PENNIEStoSTACKS 05/07/21 04:18:47 PM
#62369   Smart Move ;-) PENNIEStoSTACKS 05/07/21 04:18:11 PM
#62368   Looking to bank a few coins here. Ya powerbattles 05/07/21 04:17:23 PM
PostSubject
Consent Preferences